Provided by Tiger Trade Technology Pte. Ltd.

Rain Enhancement Technologies

0.9094
+0.04385.06%
Volume:78.10K
Turnover:68.79K
Market Cap:10.64M
PE:-0.61
High:0.9199
Open:0.8795
Low:0.8510
Close:0.8656
52wk High:8.52
52wk Low:0.7910
Shares:11.70M
Float Shares:4.80M
Volume Ratio:0.21
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5026
EPS(LYR):-1.1984
ROE:-97.04%
ROA:-337.18%
PB:-0.88
PE(LYR):-0.76

Loading ...

Company Profile

Company Name:
Rain Enhancement Technologies
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
- -
Office Location:
4851 Tamiami Trail N,Suite 200,Naples,Florida,United States
Zip Code:
34103
Fax:
- -
Introduction:
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

Directors

Name
Position
Harry L. You
Chairman and Director
Randy Seidl
Chief Executive Officer and Director
Alexandra Steele
Independent Director
Bob Reardon
Independent Director
David C. Sylvester
Independent Director
Lyman Dickerson
Independent Director
Marcus Peperzak
Independent Director
Christopher Riley
Director

Shareholders

Name
Position
Randy Seidl
Chief Executive Officer and Director
Oanh Truong
Interim Chief Financial Officer